Growth hormone for optimization of refractory heart failure treatment
It has been reported that growth hormone may benefit selected patients with congestive heart failure. A 63-year-old man with refractory congestive heart failure waiting for heart transplantation, depending on intravenous drugs (dobutamine) and presenting with progressive worsening of the clinical st...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Cardiologia (SBC)
1999-10-01
|
| Series: | Arquivos Brasileiros de Cardiologia |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999001000007 |
| _version_ | 1818847861006139392 |
|---|---|
| author | Edimar Alcides Bocchi Zyun Massuda Guimarães Guilherme Dirceu Carrara Giovanni Bellotti Amilcar Mocelin Carlos Roberto Martins Rodrigues Sobrinho José Franchini Ramires |
| author_facet | Edimar Alcides Bocchi Zyun Massuda Guimarães Guilherme Dirceu Carrara Giovanni Bellotti Amilcar Mocelin Carlos Roberto Martins Rodrigues Sobrinho José Franchini Ramires |
| author_sort | Edimar Alcides Bocchi |
| collection | DOAJ |
| description | It has been reported that growth hormone may benefit selected patients with congestive heart failure. A 63-year-old man with refractory congestive heart failure waiting for heart transplantation, depending on intravenous drugs (dobutamine) and presenting with progressive worsening of the clinical status and cachexia, despite standard treatment, received growth hormone replacement (8 units per day) for optimization of congestive heart failure management. Increase in both serum growth hormone levels (from 0.3 to 0.8 mg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion. Left ventricular ejection fraction (by MUGA) increased from 13 % to 18 % and to 28 % later, in association with reduction of pulmonary pressures and increase in exercise capacity (rise in peak VO2 to 13.4 and to 16.2ml/kg/min later). The patient was "de-listed" for heart transplantation. Growth hormone may benefit selected patients with refractory heart failure. |
| first_indexed | 2024-12-19T06:08:10Z |
| format | Article |
| id | doaj.art-68b08e67b81b440d9d87afe03c0dbc4d |
| institution | Directory Open Access Journal |
| issn | 0066-782X 1678-4170 |
| language | English |
| last_indexed | 2024-12-19T06:08:10Z |
| publishDate | 1999-10-01 |
| publisher | Sociedade Brasileira de Cardiologia (SBC) |
| record_format | Article |
| series | Arquivos Brasileiros de Cardiologia |
| spelling | doaj.art-68b08e67b81b440d9d87afe03c0dbc4d2022-12-21T20:33:04ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia0066-782X1678-41701999-10-0173439539810.1590/S0066-782X1999001000007Growth hormone for optimization of refractory heart failure treatmentEdimar Alcides BocchiZyun MassudaGuimarães GuilhermeDirceu CarraraGiovanni BellottiAmilcar MocelinCarlos Roberto Martins Rodrigues SobrinhoJosé Franchini RamiresIt has been reported that growth hormone may benefit selected patients with congestive heart failure. A 63-year-old man with refractory congestive heart failure waiting for heart transplantation, depending on intravenous drugs (dobutamine) and presenting with progressive worsening of the clinical status and cachexia, despite standard treatment, received growth hormone replacement (8 units per day) for optimization of congestive heart failure management. Increase in both serum growth hormone levels (from 0.3 to 0.8 mg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion. Left ventricular ejection fraction (by MUGA) increased from 13 % to 18 % and to 28 % later, in association with reduction of pulmonary pressures and increase in exercise capacity (rise in peak VO2 to 13.4 and to 16.2ml/kg/min later). The patient was "de-listed" for heart transplantation. Growth hormone may benefit selected patients with refractory heart failure.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999001000007 |
| spellingShingle | Edimar Alcides Bocchi Zyun Massuda Guimarães Guilherme Dirceu Carrara Giovanni Bellotti Amilcar Mocelin Carlos Roberto Martins Rodrigues Sobrinho José Franchini Ramires Growth hormone for optimization of refractory heart failure treatment Arquivos Brasileiros de Cardiologia |
| title | Growth hormone for optimization of refractory heart failure treatment |
| title_full | Growth hormone for optimization of refractory heart failure treatment |
| title_fullStr | Growth hormone for optimization of refractory heart failure treatment |
| title_full_unstemmed | Growth hormone for optimization of refractory heart failure treatment |
| title_short | Growth hormone for optimization of refractory heart failure treatment |
| title_sort | growth hormone for optimization of refractory heart failure treatment |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X1999001000007 |
| work_keys_str_mv | AT edimaralcidesbocchi growthhormoneforoptimizationofrefractoryheartfailuretreatment AT zyunmassuda growthhormoneforoptimizationofrefractoryheartfailuretreatment AT guimaraesguilherme growthhormoneforoptimizationofrefractoryheartfailuretreatment AT dirceucarrara growthhormoneforoptimizationofrefractoryheartfailuretreatment AT giovannibellotti growthhormoneforoptimizationofrefractoryheartfailuretreatment AT amilcarmocelin growthhormoneforoptimizationofrefractoryheartfailuretreatment AT carlosrobertomartinsrodriguessobrinho growthhormoneforoptimizationofrefractoryheartfailuretreatment AT josefranchiniramires growthhormoneforoptimizationofrefractoryheartfailuretreatment |